Loading
Jeffrey Graybill - Immatics

Jeffrey Graybill

Vice President, CMC Commercial Strategy, Immatics
United States

Jeffrey Graybill is Vice President, CMC Commercial Strategy at Immatics, where he leads Operations and Manufacturing readiness activities supporting the planned launch of anzu-cel, Immatics' Phase 3 TCR-T therapy for melanoma.​

Prior to joining Immatics, Jeff held cross-functional CMC Operations leadership roles at Bristol Myers Squibb, supporting the global launch and lifecycle management of Breyanzi®, the company's first CAR-T cell therapy. Earlier in his career, he held Supply Chain and Operations positions at Amgen, with responsibilities spanning clinical supply chain, project management, and medical device development.​

Jeff holds a Master of Bioscience degree from Keck Graduate Institute and a Bachelor of Science in Bioengineering from Louisiana State University.​

Sessions